征稿已开启

查看我的稿件

注册已开启

查看我的门票

已截止
活动简介

WELCOME TO SINGAPORE HEPATOLOGY CONFERENCE AND THE BEST OF EASL 2017!

SHC 2017 will be expanded to include topics such as liver cancer, cirrhosis and fatty liver due to an increase in requests for a broader conference. There has been increasing interest in HBV Cure, and after discussion with ICE-HBV and EASL, SHC 2017 will introduce a parallel track – the “Science of HBV Cure”. Consequently, the Conference has been renamed as Singapore Hepatology Conference.

SHC will to focus on HCV and HBV treatment and difficult to treat areas. The clinical meeting will continue with updates, case discussion and expert forums, a highly successful, interactive and engaging format that has been used the last 3 years.

The European Association for the Study of the Liver (EASL) has partnered with SHC since 2015 and will continue to support SHC on an even stronger collaboration for the 2017 meeting.

The 3rd Singapore Hepatitis Conference and the best of EASL (SHC-EASL) 2016 was an outstanding success with over 400 participants from 26 countries. The conference also featured 22 internationally renowned speakers and consisted of plenary sessions, case discussions, debates and poster presentations. . The scientific programme provided a multi-disciplinary approach to the assessment, diagnosis and treatment strategies to eradicate HBV and HCV.

征稿信息

征稿范围

The 2017 Conference has the following exciting Topic Highlights:

  • Evolving HBV therapy - combination and stopping NA
  • Future treatments for HBV
  • HCC debate: East vs West
  • DAA difficult to treat cases
  • DAA treatment failures and resistance
  • HCC immunotherapy
  • Fatty liver disease in Asia
  • Therapeutic advances in NASH
留言
验证码 看不清楚,更换一张
全部留言
重要日期
  • 会议日期

    06月02日

    2017

    06月03日

    2017

  • 06月03日 2017

    注册截止日期

移动端
在手机上打开
小程序
打开微信小程序
客服
扫码或点此咨询